[ad_1]
An experimental drug originally developed for the treatment of influenza has shown promising results in fighting the SARS-CoV-2 virus and could have a dual effect on COVID-19, German scientists have announced.
In vitro experiments have shown that the drug, called zapnometinib or ATR-002, can inhibit the spread of the virus to cells and at the same time reduce the over-immune response that affects the development of more severe forms of coronavirus.
The active substance zapnometinib, which was originally used in the development of an influenza drug, has been shown to be effective in various cell culture models, including activity against all tested variants of SARS-CoV-2.
This implies wide application in the treatment of future variants of the coronavirus that we will encounter in the future. Animal testing is currently underway to confirm the findings.
The results of the study, published last week in the journal Cellular and Molecular Life Sciences, are a good basis for the German Institute for Drugs and Medical Devices to approve Atriva Therapeutics to test the drug in humans.
“For the first time, we see that every existing drug shows a dual effect against COVID-19,” said study co-author Stephan Ludwig, a virologist at the Institute of Virology, University of Muenster.
“Positive results from an ongoing human clinical trial could result in urgent drug approval as early as this year,” Ludwig said.
top channel
[ad_2]
Source link
